Min Cui, Ph.D.
Managing Director, De Cheng Capital
Dr. Min Cui is the Founding Partner and Managing Director of Decheng Capital.
He also serves as a member of the Board of Directors for several companies such as GenapSys, GeneWeave Biosciences (acquired by Roche for $425M), Ketai Medical, Shenzhen GeneMDx Biotechnology, Accuragen and Sinomed.
Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm, and was focused on evaluating investment opportunities and initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that were approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005, respectively. In these positions, he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America.
His investment portfolio also includes Ion Torrent Systems (acquired by Life Technologies for $725M), GenturaDx (acquired by Luminex), China Biologic Products (NASDAQ: CBPO), Epizyme (NASDAQ: EPZM), and Sunesis (NASDAQ: SNSS).
Dr. Cui received his PhD in Cancer Biology from Stanford University, and his BS in Molecular Biology from Peking University.